Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Yeo

Showing results (151-160 of 156) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 156 results.
Poultry Science|September 20, 2012
Effect of intranasal administration of Lactobacillus fermentum CJL-112 on horizontal transmission of influenza virus in chickensH-N Youn, Y-N Lee, D-H Lee, et al.
Ebiomedicine|September 20, 2024
Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancerTrinh T T Tran, Cao Dai Phung, Brendon Z J Yeo, et al.
The Journal of Infectious Diseases|January 22, 2014
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyAntonella Castagna, Franco Maggiolo, Giovanni Penco, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 18, 2025
Safety and efficacy of KRAS antisense oligonucleotides and RIG-I agonists delivered by extracellular vesicles for pancreatic cancer peritoneal metastasis treatmentTram T T Nguyen, Xuan T T Dang, Cao Dai Phung, et al.
Cancer Treatment and Research Communications|March 29, 2026
Gain of chromosome 1q and MYCN characterize unique subgroups of Asian Wilms tumor patientsMeng Kang Wong, Kia Teng Lim, Đỗ Thị Ngọc Thùy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialR A Soo, J-Y Han, U Dafni, et al.
Pageof 16

Showing results (151-160 of 156) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 156 results.
Poultry Science|September 20, 2012
Effect of intranasal administration of Lactobacillus fermentum CJL-112 on horizontal transmission of influenza virus in chickensH-N Youn, Y-N Lee, D-H Lee, et al.
Ebiomedicine|September 20, 2024
Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancerTrinh T T Tran, Cao Dai Phung, Brendon Z J Yeo, et al.
The Journal of Infectious Diseases|January 22, 2014
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyAntonella Castagna, Franco Maggiolo, Giovanni Penco, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 18, 2025
Safety and efficacy of KRAS antisense oligonucleotides and RIG-I agonists delivered by extracellular vesicles for pancreatic cancer peritoneal metastasis treatmentTram T T Nguyen, Xuan T T Dang, Cao Dai Phung, et al.
Cancer Treatment and Research Communications|March 29, 2026
Gain of chromosome 1q and MYCN characterize unique subgroups of Asian Wilms tumor patientsMeng Kang Wong, Kia Teng Lim, Đỗ Thị Ngọc Thùy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trialR A Soo, J-Y Han, U Dafni, et al.
Pageof 16